1. Search Result
Search Result
Results for "

Carboxyethyl-γ-aminobutyric acid

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4146

    BI 456906

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A

    BI 456906 TFA

    GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-W593287

    Biochemical Assay Reagents Others
    4-Nitrophenyl2,6-di-O-benzoyl-a-D-galactopyranoside is a biochemical assay reagent.
    Carboxyethyl-γ-aminobutyric acid
  • HY-W698901

    Biochemical Assay Reagents Others
    Carboxyethyl-γ-aminobutyric acid is a biochemical assay reagent.
    β-D-Glucopyranoside,octyl 2-(acetylamino)-2-deoxy,3,4,6-triacetate
  • HY-P10876

    Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P10341

    GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022